Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection

Journal of Immunology

Volumn 177, Issue 1, 2006, Pages 162-168

  Chen, Peter W ^a   Uno, Toshihiko ^b   Ksander, Bruce R ^c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; GENE EXPRESSION; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; TUMOR ESCAPE;

EID: 33745312287     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.1.162     Document Type: Article

References (33)

1. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3: 999-1005.
2. Phillips, R. E. 2002. Immunology taught by Darwin. Nat. Immunol. 3: 987-989.
3. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70.
4. Marincola, F. M., E. M. Jaffee, D. J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74: 181-273.
5. Yefenof, E., L. J. Picker, R. H. Scheuermann, T. F. Tucker, E. S. Vitetta, and J. W. Uhr. 1993. Cancer dormancy: isolation and characterization of dormant lymphoma cells. Proc. Nat. Acad. Sci. USA 90: 1829-1833.
6. Marches, R., R. H. Scheuermann, and J. W. Uhr. 1998. Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM. Cancer Res. 58: 691-697.
7. Coudert, J. D., J. Zimmer, E. Tomasello, M. Cebecauer, M. Colonna, E. Vivier, and W. Held. 2005. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106: 1711-1717.
8. Chansac, B. M., A. Moretta, I. Vergnon, P. Opolon, Y. Lécluse, D. Grunenwald, M. Kubin, J. Soria, S. Chouaib, and F. Mami-Chouaib. 2005. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J. Immunol. 175: 5790-5798.
9. Chen, P. W., and B. R. Ksander. 2006. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Curr. Eye Res. 31; 43-55.
10. Niederkorn, J. Y., and J. W. Streilein. 1983. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J. Immunol. 131: 2587-2594.
11. Maryanski, J. L., J. Van Snick, J. C. Cerottini, and T. Boon. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur. J. Immunol. 12: 401-406.
12. Uno, T., P. W. Chen, T. G. Murray, E. R. Podack, and B. R. Ksander. 1997. Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector. Invest. Ophthalmol. Vis. Sci. 38: 2531-2539.
13. - mutation. Proc. Nat. Acad. Sci. USA 85: 2274-2278.
14. Van den Eynde, B., B. Lethe, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173: 1373-1384.
15. Boon, T., E. De Plaen, C. Lurquin, B. Van den Eynde, P. van der Bruggen, C. Traversari, A. Amar-Costesec, and A. Van Pel. 1992. Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Sum. 13: 23-37.
16. - transplantation antigens P91A, P35B, and P198. Immunogenetics 35: 316-323.
17. Lethe, B., B. van den Eynde, A. van Pel, G. Corradin, and T. Boon. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22: 2283-2288.
18. Brichard, V. G., G. Warnier, A. Van Pel, G. Morlighem, S. Lucas, and T. Boon. 1995. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur. J. Immunol. 25: 664-671.
19. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156: 1095-1100.
20. Bilsborough, J., A. Van Pel, C. Uyttenhove, T. Boon, and B. J. Van den Eynde. 1999. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J. Immunol. 162: 3534-3540.
21. Campoli, M., C. C. Chang, and S. Ferrone. 2002. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20: A40-A45.
22. Algarra, I., A. Garcia-Lora, T. Cabrera, F. Ruiz-Cabello, and F. Garrido. 2004. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53: 904-910.
23. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
24. Ahmad, M., R. C. Rees, and S. A. Ali. 2004. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 53: 844-854.
25. Pawelec, G. 2004. Immunotherapy and immunoselection-tumour escape as the final hurdle. FEBS Lett. 567: 63-66.
26. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669-1678.
27. Khong, H. T., Q. J. Wang, and S. A. Rosenberg. 2004. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J. Immunother. 27: 184-190.
28. Chang, C. C., M. Campoli, N. P. Restifo, X. Wang, and S. Ferrone. 2005. Immune selection of hot-spot β 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J. Immunol. 174: 1462-1471.
29. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
30. Apte, R. S., D. Sinha, E. Mayhew, G. J. Wistow, and J. Y. Niederkom. 1998. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J. Immunol. 160: 5693-5696.
31. Repp, A. C, E. S. Mayhew, S. Apte, and J. Y. Niederkom. 2000. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 165: 710-715.
32. Li, E. 1999. The mojo of methylation. Nat. Genet. 23: 5-6.
33. Bird, A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev. 16: 6-21.